Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen-Cilag International NV
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Study of the Effectiveness and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Under the Skin of Patients with Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy Klinické hodnocení účinnosti a bezpečnosti ustekinumabu (STELARA®) a CNTO 1959 podávaných podkožně pacientům s aktivní revmatoidní artritidou při souběžné léčbě methotrexátem
The primary objective of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in subjects with active rheumatoid arthritis (RA) despite con...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A first-in-human study to evaluate the clinical activity of JNJ-63723283 in patients with advanced cancers. Estudio de primera administración en humanos para evaluar la actividad clínica de JNJ-63723283 en sujetos con cáncer avanzado
• To identify the recommended Phase 2 dose(s) (RP2D[s]) for JNJ-63723283 (Part 1) • To assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in subjects with selected advanced cancers includin...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001
The primary objective is to demonstrate the efficacy using 2 co-primary endpoints (as measured by the changes from baseline to the end of Week 16 in Western Ontario and McMaster University Osteoarthri...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma (CTCL)
The primary objective is to determine the overall cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT) criteria.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
4
5
6
7
8
9
10
11
12
13